FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
Previous studies provide a strong theoretical rationale for the conduct of a randomized study
evaluating the efficacy and safety of ramucirumab in combination with FLOT in the
perioperative treatment of resectable adenocarcinoma of the stomach or GEJ.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Krankenhaus Nordwest